Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment

Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment

BACKGROUND: Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder with heterogeneous biological and clinical features. The biomolecular mechanisms of CML response to tyrosine-kinase inhibitors are not fully defined. OBJECTIVE: We undertook a gene expression profiling (GEP) study of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer biomarkers : section A of Disease markers 2017-12, Vol.21 (1), p.41-53
Hauptverfasser: Trojani, Alessandra, Pungolino, Ester, Rossi, Giuseppe, D’Adda, Mariella, Lodola, Milena, Camillo, Barbara Di, Perego, Alessandra, Turrini, Mauro, Orlandi, Ester, Borin, Lorenza, Iurlo, Alessandra, Malato, Simona, Spina, Francesco, Latargia, Maria Luisa, Lanza, Francesco, Artale, Salvatore, Anghilieri, Michela, Carraro, Maria Cristina, Canal, Gabriella De, Morra, Enrica, Cairoli, Roberto
Format: Artikel
Sprache:eng
Schlagworte:
Antigens, CD34 - blood
Bone marrow
Bone Marrow Cells - metabolism
Bone Marrow Cells - pathology
CD34 antigen
Chronic myeloid leukemia
Diagnosis
Gene expression
Gene Expression Profiling - methods
Gene Expression Regulation, Leukemic - drug effects
Humans
Inhibitor drugs
Kinases
Leukemia
Leukemia, Myeloid, Chronic-Phase - blood
Leukemia, Myeloid, Chronic-Phase - drug therapy
Leukemia, Myeloid, Chronic-Phase - genetics
Leukocyte Count
Myeloid leukemia
Myeloproliferative diseases
Patients
Protein-Tyrosine Kinases - therapeutic use
Pyrimidines - therapeutic use
Targeted cancer therapy
Time Factors
Treatment Outcome
Tyrosine
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:BACKGROUND: Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder with heterogeneous biological and clinical features. The biomolecular mechanisms of CML response to tyrosine-kinase inhibitors are not fully defined. OBJECTIVE: We undertook a gene expression profiling (GEP) study of selected bone marrow (BM) CD34+/lin- cells of chronic-phase CML patients at diagnosis and after 12 months of TKI nilotinib to investigate molecular signatures characterizing both conditions.
ISSN:1574-0153
1875-8592
DOI:10.3233/CBM-170209